Summary & Overview
CPT 88177: Cytopathology Rapid On-Site Evaluation, Additional Episode
CPT code 88177 covers additional immediate technical evaluations of cytopathology specimens from fine needle aspirates to determine specimen adequacy. The code is used when a laboratory analyst performs separate additional evaluation episodes on the same site after the initial assessment. Nationally, this code matters because on-site adequacy assessments impact diagnostic yield, procedure repeat rates, and downstream pathology workflows.
Key payers in typical coverage analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise description of the clinical context for on-site cytopathology evaluation, the typical service setting, and the types of benchmarks and policy elements often examined for this service. Content commonly covered alongside this code includes utilization benchmarks for on-site adequacy assessments, payer coverage policies and allowed services, bundling and billing guidance for repeat evaluation episodes, and clinical workflow considerations tied to procedural efficiency and diagnostic accuracy.
Data not available in the input for payer-specific rates, associated taxonomies, and ICD-10 diagnoses are noted as unavailable. The publication focuses on national clinical and billing context, common modifiers and coding associations, and where to expect policy considerations relevant to pathology departments, outpatient clinics, and payers.
Billing Code Overview
CPT code 88177 describes a technical cytopathology evaluation performed by a laboratory analyst on a fine needle aspirate specimen to determine immediately whether a satisfactory sample is present for diagnosis. This code is reported for each separate additional evaluation episode after the first on the same site.
-
Service type: Immediate technical cytopathology evaluation of fine needle aspirate (additional evaluation episodes)
-
Typical site of service: Pathology or cytology laboratory, procedure suite, clinic, or outpatient setting where fine needle aspiration is performed and immediate specimen adequacy assessment is required.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient presents to an outpatient interventional radiology suite with a palpable thyroid nodule identified on ultrasound. The clinician performs a fine needle aspiration (FNA) of the nodule with immediate on-site evaluation (ROSE) by a cytotechnologist. The cytology laboratory analyst performs a rapid technical preparation and staining of the aspirate and examines the specimen microscopically to determine specimen adequacy. If the first pass is inadequate, the clinician obtains additional passes and the lab analyst performs separate immediate evaluations for each additional pass at the same site. The service is typically billed by hospital or independent pathology laboratories supporting outpatient clinics, ambulatory surgical centers, or radiology suites during procedures such as thyroid, lymph node, or lung FNA. The typical workflow: clinician obtains aspirate → sample sent to lab analyst for rapid on-site technical evaluation (88177) → results reported immediately to clinician to guide additional sampling or end procedure → final cytology interpreted later by pathologist.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional interpretation component if separated from the technical component by another provider. |
59 | Distinct procedural service | Use when 88177 is billed for an additional, separate evaluation episode that is distinct from other services on the same day. |
76 | Repeat procedure by same physician | Use when the same provider repeats the immediate evaluation at the same site during the same encounter for an additional aspirate. |
78 | Unplanned return to the operating/procedure room by same physician following initial procedure | Use when an unplanned separate evaluation episode occurs intra-procedurally requiring return to procedure area. |
91 | Repeat clinical diagnostic laboratory test | Use when a repeat rapid evaluation is performed and documented as a separate laboratory repeat. |
90 | Reference (outside) laboratory | Use when the technical component was performed by an outside laboratory and billing reflects that arrangement. |
QX | Modifier indicating CLIA-waived/qualified non-physician staff performs test under CLIA | Use when the technical rapid on-site evaluation is performed by a qualified non-physician staff under appropriate CLIA rules. |
QY | CLIA certificate of compliance | Use when the performing laboratory holds a CLIA certificate of compliance for this test. |
TC | Technical component | Use when billing only the technical portion of the service (the lab analyst’s hands-on evaluation). |
RT | Right side (not in provided list) | Data not available in the input. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207RX0400X | Pathology | Anatomic and Clinical Pathology specialists oversee cytology services and interpret final FNA cytology. |
208400000X | Diagnostic Radiology | Radiologists commonly perform image-guided FNAs (thyroid, lung) and coordinate ROSE. |
363A00000X | Cytopathology (Laboratory) | Cytotechnologists and laboratory personnel perform rapid on-site technical evaluations billed under 88177. |
207L00000X | Anatomic Pathology | Provides final diagnostic reads and correlates ROSE findings with permanent preparations. |
2086S0105X | Interventional Radiology | Interventional radiologists perform FNAs in procedural suites and rely on immediate cytology adequacy assessments. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
R22.1 | Localized swelling, mass and lump, neck | Common indication for thyroid or cervical lymph node FNA where immediate adequacy assessment guides sampling. |
E04.1 | Nontoxic single thyroid nodule | Frequent clinical diagnosis prompting thyroid FNA with on-site adequacy evaluation. |
C73 | Malignant neoplasm of thyroid gland | Suspicious or known thyroid malignancy requiring FNA and immediate assessment to ensure diagnostic material. |
R59.0 | Localized enlarged lymph nodes | Lymph node FNA often uses ROSE to confirm diagnostic cellularity during the procedure. |
J98.4 | Other disorders of lung, not elsewhere classified (eg, suspicious pulmonary nodule) | Pulmonary or mediastinal FNA/biopsy with ROSE to confirm adequate material for cytology. |
D34 | Benign neoplasm of thyroid gland | Benign nodules commonly undergo FNA for diagnosis; immediate evaluation may reduce repeat procedures. |
R91.8 | Other nonspecific abnormal finding of lung field | Imaging-detected lung lesions often sampled with FNA and assessed on-site for adequacy. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
10022 | Fine needle aspiration; without imaging guidance | Represents the clinician-performed FNA procedure that generates the specimen evaluated by 88177. |
10005 | Fine needle aspiration biopsy, without imaging guidance; first lesion | Alternatively used for FNA of initial lesion; associated with specimen adequacy assessment by 88177. |
88172 | Cytopathology, smears and/or fluid cytology, interpretation by pathologist or cytotechnologist; immediate cytologic evaluation | Often reported for the interpretive component or initial rapid on-site evaluation; 88177 is used for each additional separate immediate evaluation episode after the first on the same site. |
88305 | Level IV surgical pathology, gross and microscopic examination | Represents subsequent formal cytopathology or surgical pathology processing and interpretation after ROSE adequacy is determined. |
76942 | Ultrasonic guidance for needle placement (ie, for biopsy, aspiration, or injection) | Commonly performed immediately before or during FNA to guide sampling that will be assessed with 88177. |
88175 | Cytopathology, slides prepared from fine needle aspirate, initial interpretation | Related initial slide preparations; 88177 applies to additional immediate evaluations beyond the first at the same site. |